<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04890964</url>
  </required_header>
  <id_info>
    <org_study_id>36995020.3.0000.5327</org_study_id>
    <nct_id>NCT04890964</nct_id>
  </id_info>
  <brief_title>Montage of HTDCS in Psycho-cognitive Functions in FM</brief_title>
  <acronym>HFTDCS</acronym>
  <official_title>Mapping the Impact of the Montage of the Transcranial Direct Current Stimulation at Home at Cortical and Psycho-cognitive Functions, Functional Capacity and Biological Rhythm in the Fibromyalgia: A Randomized, Factorial, Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to map the impact of anodic transcranial direct current stimulation (tDCS)&#xD;
      for prolonged home use applied to the primary motor cortex and the left dorsolateral&#xD;
      prefrontal córtex (DLPFC), compared to the respective treatments simulated in fibromyalgia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to map the impact of anodic tDCS for prolonged home use applied to the&#xD;
      primary motor cortex and the left dorsolateral prefrontal córtex (DLPFC), compared to the&#xD;
      respective treatments simulated in fibromyalgia, targeting the outcomes of the following&#xD;
      axes: (1) pain intensity and functional capacity; (2) psycho cognitive functions; (3)&#xD;
      neurophysiological markers; (4) biological rhythm markers; (5) to map the potential of&#xD;
      neurophysiological markers, biological rhythm and history of trauma in childhood and&#xD;
      adolescence in functional capacity, depressive symptoms and working memory tests.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">December 10, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 10, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>HB-a-tDCS - M1 (n=33); HB-s-tDCS - M1 (n=17); HB-a-tDCS-DLPFC (n=33); HB-a-tDCS- DLPFC (n=17)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>A randomized, double-blind, factorial, parallel-group, controlled trial with simulated treatment will be performed. The study follows the CONSORT guideline and will be registered in the ClinicalTrials.gov database: Home</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>level of pain</measure>
    <time_frame>Up to 60 minutes before and after tDCS stimulation</time_frame>
    <description>response on the Numeric Verbal Scale (NPS) from 0-10 during the conditioning stimulus</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Psychocognitive functions</measure>
    <time_frame>Pre and Pos 20 days Intervention</time_frame>
    <description>episodic memory measured by Rey Verbal test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>circadian rhythmicity</measure>
    <time_frame>Pre and Pos 20 days Intervention</time_frame>
    <description>urinary 6-sulfatoxymelatonin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of tDCS over DLPFC on cognitive function.</measure>
    <time_frame>Pre and Pos 20 days Intervention</time_frame>
    <description>Cortical connectivity</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>Transcranial Direct Current Stimulation (tDCS), Active Stimulation - DLPFC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received Active stimulation 20 minutes daily for 20 days, and 4 times after continuous stimulation, every 15 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transcranial Direct Current Stimulation (tDCS), Sham Stimulation - DLPFC</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Participants received Sham stimulation 20 minutes daily for 20 days, and 4 times after continuous stimulation, every 15 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transcranial Direct Current Stimulation (tDCS), Active Stimulation - M1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received Active stimulation 20 minutes daily for 20 days, and 4 times after continuous stimulation, every 15 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transcranial Direct Current Stimulation (tDCS), Sham Stimulation - M1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received Sham stimulation 20 minutes daily for 20 days, and 4 times after continuous stimulation, every 15 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial Direct Current Stimulation (tDCS)</intervention_name>
    <description>A stimulation device, that releases 2.0mA current by a 35 cm2 electrode direct located on a specific location on the scalp for 20 minutes</description>
    <arm_group_label>Transcranial Direct Current Stimulation (tDCS), Active Stimulation - DLPFC</arm_group_label>
    <arm_group_label>Transcranial Direct Current Stimulation (tDCS), Active Stimulation - M1</arm_group_label>
    <arm_group_label>Transcranial Direct Current Stimulation (tDCS), Sham Stimulation - DLPFC</arm_group_label>
    <arm_group_label>Transcranial Direct Current Stimulation (tDCS), Sham Stimulation - M1</arm_group_label>
    <other_name>tDCS</other_name>
    <other_name>Non Invasive Brain Stimulation (NIBS)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women aged 30 to 65 years; who can read and write, with a confirmed diagnosis of FM&#xD;
             according to the criteria of the American College of Rheumatology (2010-2016). Pain&#xD;
             score equal to or greater than six on the Numeric Pain Scale (NPS 0-10) on most days&#xD;
             in the last 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Living outside Porto Alegre area and pregnancy.&#xD;
&#xD;
          -  Contraindications to TMS and tDCS: metallic implant in the brain; medical devices&#xD;
             implanted in the brain, cardiac pacemaker; aneurysmal clip; metallic cochlear&#xD;
             prosthesis, ear implants, and non-removable hearing aids; infusion pumps (including&#xD;
             implantable); cranial halos. Pregnant women, shift work, use of exogenous melatonin,&#xD;
             history of alcohol or drug abuse in the last 6 months, neurological pathologies,&#xD;
             history of head trauma or neurosurgery, decompensated systemic chronic diseases,&#xD;
             chronic inflammatory diseases (lupus, rheumatoid arthritis, Reiter's syndrome),&#xD;
             personal history of cancer, past or under treatment.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>We have chosen women over men, due to the prevalence of the disease that we are researching and also because the symptoms characteristics are more homogeneous.</gender_description>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolnei Caumo, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Clinicas de Porto Alegre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wolnei Caumo, Dr.</last_name>
    <phone>+555199813977</phone>
    <email>wcaumo@hcpa.edu.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90.450-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolnei Caumo, PhD</last_name>
      <phone>+5551 3359 6377</phone>
      <email>wcaumo@hcpa.edu.br</email>
    </contact>
    <investigator>
      <last_name>Wolnei Caumo, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 24, 2021</study_first_submitted>
  <study_first_submitted_qc>May 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2021</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fibromyalgia</keyword>
  <keyword>chronic pain</keyword>
  <keyword>tDCS</keyword>
  <keyword>TMS</keyword>
  <keyword>BDNF</keyword>
  <keyword>cortical connectivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

